Preventive Cardiology Through Fresh Eyes: Highlights From ASPC’s 2025 Congress

The American Society for Preventive Cardiology marked its 40th anniversary this year at the ASPC Congress on CVD Prevention in Boston, held August 1-3, with 3 days of debates, presentations, oral abstracts, and posters focused on improving outcomes for patients with cardiovascular diseases through both traditional and new methods. Four first-time attendees sat for discussions with The American Journal of Managed Care^®, and here they reflect on what brought them to Boston.

Transcripts were lightly edited for clarity; captions were auto-generated.

Transcript

As a first-time attendee, what have you found most valuable about the ASPC Congress on CVD Prevention?

Alexandra M. Trevino, MD: I'm really excited to be here. There's a lot of cutting-edge research that's going on, and I'm excited to know its applicability to clinical medicine so that I can take it home in the treatment of my patients, back in Chicago. Also just the opportunity to meet the field's best and brightest and get to know some of the leaders in the field.

Khush Kharidia, MD: I really wanted to attend, because one, I'm really excited and interested in preventive cardiology. A lot of times when we see patients in the cardiac ICUs [intensive care units], and sometimes even our clinics, they are just at such a later stage of their disease, and I got more interested in what can we do from day one, what can we do to help patients and people in general to live healthy lifestyles so they don't end up in that last stage. That's what really interested me in prevention and in this conference in general.

A lot of my mentors are here and I was really interested in some of the cool talks and the fun stuff that's up and coming in preventive cardiology. I was really excited to attend for that reason, and I really wanted to talk about this project as well and share with the ASPC how TikTok can influence health. That's why I'm here.

Varsha Tanguturi, MD: I think that prevention is critical to how we deliver care for the future, meaning for the future of patients' health, and so learning how to intervene upstream of the end stage of disease is really important. I think the field of prevention has done this really, really well in managing hyperlipidemia and hypertension and showing the effect of that over time. I'd love for us to bring some of that work to valvular heart disease to be able to stay ahead of it.

Vivek Bhalla, MD: One of the most valuable aspects was some of the content that was provided. There were sessions on artificial intelligence [AI], use of AI in diagnosis, that I thought to be very interesting, as well as there was a session on GLP-1 [glucagon-like peptide 1] agonists, on incretin-based therapies, which was very educational for me. I found the content in particular. I think the panel of speakers that we had were excellent, physicians or other providers that have expertise in their areas. Hearing from them firsthand about their thoughts was amazing.